10-K: Collegium Pharma Reports Strong 2025 Revenue Growth, Driven by Jornay PM

Collegium Pharmaceutical, Inc. announced a significant increase in net product revenues for 2025, primarily fueled by the full-year contribution of Jornay PM and strategic acquisitions.

Summary

• Net product revenues increased by $149.2 million to $780.6 million in 2025 from $631.4 million in 2024.
• Jornay PM revenue increased by $111.7 million in 2025, primarily due to a full year of sales following its acquisition in September 2024.
• Nucynta Products revenue increased by $19.8 million, driven by lower gross-to-net adjustments and higher gross price, despite lower sales volume.
• Belbuca revenue increased by $10.4 million, also due to lower gross-to-net adjustments and higher gross price, despite lower sales volume.
• Xtampza ER revenue increased by $8.0 million, primarily from lower gross-to-net adjustments, including $3.2 million from rebate settlements, and higher gross price, despite lower sales volume.
• Net income decreased to $62.87 million in 2025 from $69.19 million in 2024.
• Adjusted EBITDA increased by $59.3 million to $460.5 million in 2025 from $401.2 million in 2024.
• The company entered into a new 2025 Credit Agreement in December 2025, comprising a $580.0 million term loan, $300.0 million in delayed draw term loan commitments, and a $100.0 million revolving credit facility.
• Cash and cash equivalents increased to $231.3 million as of December 31, 2025, from $70.6 million as of December 31, 2024.
• A new share repurchase program of up to $150.0 million was authorized in July 2025, with the full $150.0 million remaining available as of December 31, 2025.
• A generic equivalent of Nucynta IR launched on February 25, 2026, and a generic version of Nucynta ER is expected to launch in the first quarter of 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing. While net income declined, strong revenue growth driven by strategic acquisitions and increased Adjusted EBITDA indicate operational strength and successful integration. However, the impact of generic competition for Nucynta and rising operating costs warrant careful monitoring.

Positives

• Net product revenues for 2025 increased significantly by $149.2 million to $780.6 million, demonstrating strong top-line growth.
• Jornay PM, acquired in September 2024, contributed substantially with a $111.7 million increase in revenue due to a full year of sales.
• Existing products Belbuca, Xtampza ER, and Nucynta Products also showed revenue increases of $10.4 million, $8.0 million, and $19.8 million, respectively.
• Adjusted EBITDA grew by $59.3 million to $460.5 million in 2025, indicating improved operational performance excluding certain non-cash and non-recurring items.
• The company's cash and cash equivalents increased substantially to $231.3 million by year-end 2025, providing strong liquidity.
• Successful refinancing of term loans with the new 2025 Credit Facility provides a $580.0 million term loan, $300.0 million delayed draw term loan commitments, and a $100.0 million revolving credit facility, enhancing financial flexibility.
• Authorization of a new $150.0 million share repurchase program signals confidence in future cash flow and commitment to shareholder returns.
• FDA granted New Patient Population exclusivity for Nucynta IR until July 3, 2026, and pediatric exclusivity for Nucynta Products until January 3, 2027 (Nucynta IR) and December 27, 2025 (Nucynta ER), extending market protection for these products.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025, indicating sound financial governance.

Negatives

• Net income decreased to $62.87 million in 2025 from $69.19 million in 2024, despite significant revenue growth.
• Cost of product revenues (excluding intangible asset amortization) increased by $6.6 million to $95.4 million in 2025.
• Intangible asset amortization increased by $56.6 million to $221.9 million, impacting profitability.
• Selling, general and administrative expenses rose by $74.4 million to $284.8 million, driven by increased headcount, sales and marketing for Jornay PM, and executive transition expenses.
• Interest expense increased by $8.3 million to $82.3 million, primarily due to higher interest on the deferred royalty obligation from the Ironshore acquisition.
• A loss on extinguishment of debt of $16.0 million was recorded in 2025 due to the repayment of the 2024 Term Loan.
• Interest income decreased by $2.7 million to $11.3 million due to lower interest rates on cash equivalents and marketable securities.
• The launch of a generic equivalent of Nucynta IR on February 25, 2026, and the expected launch of a generic Nucynta ER in Q1 2026, will likely lead to a decline in net revenue for the Nucynta Products.
• An impairment expense of $575,000 was recognized for the right-of-use asset associated with the Ironshore Lease.

Risks

• The ability to maintain profitability is dependent on the successful commercialization of current and future acquired products.
• Substantial outstanding indebtedness, including a $580.0 million Term Loan and $241.5 million convertible notes, may adversely affect business, financial condition, and results of operations.
• Adverse developments in the financial services industry could impair access to funding sources and credit arrangements.
• Additional data may emerge that could change the FDA's position on product labeling, including abuse-deterrent claims for Xtampza ER, potentially impacting marketability.
• Opioid products are subject to mandatory Risk Evaluation and Mitigation Strategy (REMS) programs, which could increase costs or reduce prescribing willingness.
• Failure to comply with ongoing governmental regulations for marketing products, particularly Xtampza ER's abuse-deterrent labeling, could lead to enforcement actions and sanctions.
• Unfavorable outcomes in intellectual property litigation could be costly and potentially limit the ability to commercialize products.
• Inability to obtain or maintain intellectual property rights for technologies and products may lead to loss of valuable assets or inability to compete effectively.
• Litigation to enforce or defend intellectual property rights is expensive, time-consuming, and may be unsuccessful.
• Failure to comply with procedural, document submission, and fee payment requirements imposed by governmental patent agencies could reduce or eliminate patent protection.
• Inability to successfully utilize internal sales and marketing capabilities or enter into strategic alliances with marketing collaborators may hinder product revenue generation.
• Lack of acceptance and use of products by the medical community, patients, and healthcare payors would negatively impact revenues and business prospects.
• Products containing controlled substances are subject to high regulation by state and federal law enforcement and other regulatory agencies, including DEA quotas, which could limit supply and commercialization.
• Current and future legislation and regulatory changes (e.g., opioid stewardship taxes, drug pricing transparency, Inflation Reduction Act, Trump Administration policies) may increase costs and reduce product prices.
• Social issues around opioid and stimulant abuse, including law enforcement concerns and negative publicity, could decrease the potential market for products and adversely impact investor perceptions.
• Approval of generic products with claims that compete with current products (e.g., Nucynta IR/ER generics) could lead to significant sales decline.
• Dependence on third-party manufacturers and sole/limited suppliers for active pharmaceutical ingredients (APIs) poses risks of production problems, higher costs, and supply chain disruptions.
• Manufacturing issues may arise that could increase product and regulatory approval costs, delay commercialization, or limit commercial supply.
• Dependence on wholesale pharmaceutical distributors for retail distribution; loss of significant distributors or disruption to their network could adversely affect financial condition and results of operations.
• Products may be subject to post-marketing requirements or commitments that may not be capable of timely or satisfactory completion without participation in consortia over which the company has limited control.
• Failure to realize all anticipated benefits from future acquisitions or successfully integrate them could adversely affect business and financial condition.
• Business may be adversely affected by certain events or circumstances outside control, including macroeconomic conditions (recession, inflation) and geopolitical turmoil.
• Security breaches and other disruptions to information technology systems may compromise information and expose the company to liability.
• The use of artificial intelligence technologies in business could expose the company to significant data privacy and regulatory risks.
• Litigation or regulatory action regarding opioid medications could negatively affect the business, reputation, results of operations, and cash flows.
• Substantial competition from other biotechnology and pharmaceutical companies, including those with greater resources or developing alternative treatments.
• Commercial sales of products may expose the company to expensive product liability claims, and insurance may not be adequate.
• Relationships with customers and payors are subject to applicable anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations, which could lead to penalties.
• Inadequate funding for the FDA, DEA, SEC, and other government agencies, including from government shutdowns, could hinder their ability to perform normal business functions.
• The price of common stock may be volatile, and investors could lose all or part of their investment.
• Anti-takeover provisions in corporate documents and Virginia law could delay or prevent an acquisition of the company.
• Failure to maintain an effective system of internal control over financial reporting could adversely affect investor confidence.
• Sales of common stock in the public market by current shareholders or the exercise of options could dilute ownership interests and adversely affect the future market price of common stock.
• There is no assurance that the company will repurchase additional shares of common stock at all or at favorable prices under its authorized programs.

Future Outlook

The company expects selling, general and administrative expenses to remain substantial due to ongoing investment in product commercialization. It anticipates incurring additional acquisition-related expenses in 2026 related to the NSP arbitration and escrow account maintenance. The launch of generic versions of Nucynta IR in February 2026 and Nucynta ER in Q1 2026 is expected to impact net revenue for the Nucynta Products. The company believes its current cash, cash equivalents, marketable securities, and expected cash inflows from operations will be sufficient to fund operating expenses, debt service, and capital expenditure requirements for the foreseeable future. However, there is uncertainty regarding the effectiveness of the DEA's increased methylphenidate quota in resolving ADHD medication supply chain disruptions and the potential impact of FDA's revised labeling for extended-release ADHD products on Jornay PM prescribing. The impact of the Inflation Reduction Act and potential new Trump Administration regulatory reforms on drug pricing and profitability also remains uncertain.

Management Comments

• Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.
• We have developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain.
• We are committed to ongoing monitoring and public dissemination of our real-world abuse and diversion data, regardless of the results (referring to Xtampza ER).
• We believe that our existing facilities are adequate for our current and expected future needs.
• We believe that our cash, cash equivalents, and marketable securities as of December 31, 2025, together with expected cash inflows from operations, will enable us to fund our operating expenses, debt service and capital expenditure requirements under our current business plan for the foreseeable future.

Industry Context

StockSavvy.ai notes that Collegium Pharmaceutical's strong revenue growth in 2025, particularly from Jornay PM, positions it well in the expanding neuropsychiatry market (ADHD), diversifying its portfolio beyond pain management. The company's continued focus on abuse-deterrent formulations for opioids like Xtampza ER aligns with FDA's comprehensive Opioids Action Plan, though the entry of generic competitors for Nucynta Products and new non-opioid analgesics like Vertex's suzetrigine highlight increasing competitive pressures and the evolving landscape of pain management. The ongoing regulatory scrutiny on drug pricing and opioid/stimulant abuse, including the Inflation Reduction Act and potential Trump Administration policies, presents a challenging environment for all pharmaceutical companies, requiring adaptive strategies for pricing, market access, and compliance.

Comparison to Industry Standards

• The company's revenue growth of 23.6% in 2025 (from $631.4 million to $780.6 million) is robust, especially compared to the broader pharmaceutical industry which often sees single-digit growth for established products.
• The acquisition of Ironshore and its Jornay PM product demonstrates a strategic move into the ADHD market, a segment with significant unmet needs and growth potential, contrasting with the more mature and heavily scrutinized opioid market.
• The launch of generic Nucynta IR by Hikma Pharmaceuticals and the anticipated launch of Nucynta ER generics in Q1 2026 are standard industry events following patent expirations, which typically lead to significant revenue erosion for branded products. This is a common challenge for pharmaceutical companies managing mature portfolios.
• The FDA's approval of Vertex Pharmaceuticals' suzetrigine as a non-opioid analgesic in January 2025 represents a significant industry shift towards non-addictive pain treatments, posing a long-term competitive threat to Collegium's opioid portfolio (Belbuca, Xtampza ER, Nucynta Products).
• The company's Consolidated First Lien Net Leverage Ratio covenant of not greater than 2.75:1.00 (with a holiday to 3.25:1.00 post-acquisition) and Fixed Charge Coverage Ratio of not less than 1.50:1.00 are typical financial covenants for leveraged pharmaceutical companies, indicating a moderate level of financial risk management.

Management Changes

Corporate Governance

Legal Proceedings

• **Xtampza ER Litigation (Purdue Pharma)**: Ongoing patent infringement lawsuits regarding U.S. Patent Nos. 9,333, 9,19, 434, and 961. Purdue seeks monetary relief, adjustment of FDA approval date, and an injunction. The company denies claims and seeks judgment of invalidity/non-infringement and attorneys' fees. Outcome uncertain.
• **Nucynta Litigation (Purdue Pharma)**: Patent infringement suit filed by Purdue in February 2018 regarding Nucynta IR/ER, asserting infringement of U.S. Patent Nos. 9,861,583, 9,867,784, and 9,872,836. Litigation is currently subject to a bankruptcy stay.
• **Grnenthal GMBH Litigation**: Filed February 2, 2026, against Collegium and Hikma Pharmaceuticals USA Inc. alleging infringement of U.S. Patent Nos. 8,536,130 and 11,344,512 by a future authorized generic launch of Nucynta ER. The company plans to vigorously defend. Outcome uncertain.
• **Opioid-Related Request and Subpoenas**: Received subpoenas/civil investigative demands from the Attorneys General of Washington, New Hampshire, and Maryland regarding opioid sales and marketing practices. The company is cooperating with investigations. Settled with the Massachusetts AG in December 2021 for $2.75 million.
• **Aquestive Litigation**: Settled on March 8, 2023, for an $8.5 million payment to Aquestive, resolving patent infringement disputes related to Bunavail and Belbuca.
• **Alvogen Litigation**: Ongoing patent infringement lawsuit regarding Belbuca. The Federal Circuit affirmed the validity of certain claims of the 866 and 539 patents, extending the FDA approval stay until December 21, 2032. Alvogen sent a new notice letter in June 2025 claiming non-infringement of the 539 patent. BDSI filed a motion to enforce the January 21, 2022 Final Judgement (denied Jan 12, 2026) and a new patent infringement lawsuit (filed July 24, 2025, with a trial date of April 12, 2027).
• **Chemo Research, S.L. Litigation**: Ongoing patent infringement lawsuit regarding Belbuca. Chemo filed an ANDA with Paragraph IV certification. The Court upheld the validity of certain BEMA patents. Chemo received multiple Complete Response Letters for amended ANDAs. Outcome uncertain.
• **David Lickrish, as legal assignee of North Sound Pharmaceuticals, Inc. (In Official Liquidation)**: Arbitration filed in May 2025 against Ironshore Pharmaceuticals & Development, Inc. (a Collegium subsidiary) alleging contract violations and business torts, seeking over $500,000 in damages. The company intends to vigorously defend. Outcome uncertain.
• **Walgreen Co. v. Collegium Pharmaceutical, Inc.**: Lawsuit filed June 2025 alleging Collegium owes over $14.0 million in credits for product returns. The Court granted Collegium's motion to dismiss for lack of personal jurisdiction on February 18, 2026, but Walgreens may file an amended complaint. Collegium's defense is tendered to a third party. Outcome uncertain.

Related Party Transactions

• The company's transactions with affiliates are generally conducted on terms and conditions not less favorable than could be obtained from unrelated third parties, as per its Related Party Transaction Policy.
• Employment, severance, and other compensatory arrangements with current or former officers, directors, employees, and consultants are made in the ordinary course of business or as approved by the board of directors.
• Transactions pursuant to equity award plans and employee benefit plans and arrangements are solely to the extent attributable to the ownership or operations of the company and its subsidiaries.

Stakeholder Impact

• **Shareholders**: Impacted by the decrease in net income, the authorization of a new share repurchase program, potential dilution from convertible notes and stock options, and the volatility of the common stock price.
• **Employees**: Affected by the company's focus on talent acquisition and retention, training and development programs, health and safety initiatives, and the provision of stock-based and cash-based compensation awards. Executive transitions also impact leadership stability.
• **Customers (Wholesalers, Pharmacies, Healthcare Professionals)**: Directly impacted by product availability, pricing strategies, marketing efforts, and compliance with regulatory changes such as REMS and product labeling updates.
• **Patients**: Directly impacted by the availability, safety, and efficacy of the company's products for ADHD and pain management, as well as access to these treatments through reimbursement and payor contracts.
• **Creditors (Lenders, Noteholders)**: Their interests are tied to the company's financial health, its ability to meet debt service obligations, and compliance with financial covenants under the new 2025 Credit Agreement and 2029 Convertible Notes.

Next Steps

• Continue commercialization efforts for Jornay PM, Belbuca, Xtampza ER, Nucynta Products, and Symproic.
• Manage the impact of generic competition for Nucynta IR (launched Feb 25, 2026) and Nucynta ER (expected Q1 2026).
• Defend against ongoing patent infringement lawsuits (e.g., Alvogen, Grnenthal, Purdue).
• Address the Walgreens lawsuit regarding product returns.
• Manage the NSP arbitration related to the Ironshore acquisition.
• Monitor and comply with evolving regulatory requirements, including FDA labeling changes for opioids and ADHD products, and drug pricing reforms.
• Potentially utilize the $300.0 million delayed draw term loan commitments for future Permitted Acquisitions and Investments.
• Execute the $150.0 million share repurchase program.

Key Dates

Recommendation

Collegium Pharmaceutical demonstrated strong revenue growth in 2025, driven by the successful integration of Jornay PM and solid performance from its existing portfolio. The increase in Adjusted EBITDA reflects operational efficiency. However, the decline in net income, coupled with increased operating expenses and significant legal challenges, particularly patent infringement lawsuits and the impending generic competition for Nucynta, introduce considerable uncertainty. While the new credit facility provides liquidity and the share repurchase program signals confidence, these are balanced by the inherent risks in the pharmaceutical industry, especially for controlled substances. A seasoned investor would likely maintain a 'hold' position, awaiting clearer outcomes on litigation, the full impact of generic competition, and the effectiveness of new product commercialization efforts.

Keywords

Pharmaceutical, Biopharmaceutical, ADHD, Pain Management, Opioid, Stimulant, Jornay PM, Belbuca, Xtampza ER, Nucynta, Symproic, SEC Filing, 10-K, Financial Results, Revenue, Net Income, Debt, Acquisitions, Intellectual Property, Regulatory, FDA, DEA, Healthcare Laws, Corporate Governance, Share Repurchase